Clinical risk–benefit assessment of dopamine agonists
Identifieur interne : 000E45 ( Main/Exploration ); précédent : 000E44; suivant : 000E46Clinical risk–benefit assessment of dopamine agonists
Auteurs : J. C. Möller [Allemagne] ; K. M. Eggert [Allemagne] ; M. Unger [Allemagne] ; P. Odin [Allemagne] ; K. R. Chaudhuri [Royaume-Uni] ; W. H. Oertel [Allemagne]Source :
- European Journal of Neurology [ 1351-5101 ] ; 2008-09.
English descriptors
- KwdEn :
Abstract
Dopamine agonists (DAs) have proven efficacy as monotherapy in early Parkinson’s disease (PD) for preventing motor complications such as dyskinesia and as adjunct therapy as the disease progresses. Further, it is increasingly evident that at least some DAs may provide additional benefits, such as reduction in depressive symptoms and treatment of refractory tremor. Different side‐effect profiles have been associated with levodopa and ergot or non‐ergot DA treatment, such as sudden onset of sleep, reduced impulse control, hallucination, and cardiovascular fibrosis. This paper discusses the evidence for specific associations between particular treatments and side effects as well as the clinical implications for patient care. Ultimately, the choice depends on the risk–benefit assessment as it applies to the individual patient’s clinical profile and the physician’s preference.
Url:
DOI: 10.1111/j.1468-1331.2008.02214.x
Affiliations:
- Allemagne, Royaume-Uni
- Angleterre, District de Giessen, Grand Londres, Hesse (Land)
- Londres, Marbourg
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clinical risk–benefit assessment of dopamine agonists</title><author><name sortKey="Moller, J C" sort="Moller, J C" uniqKey="Moller J" first="J. C." last="Möller">J. C. Möller</name></author><author><name sortKey="Eggert, K M" sort="Eggert, K M" uniqKey="Eggert K" first="K. M." last="Eggert">K. M. Eggert</name></author><author><name sortKey="Unger, M" sort="Unger, M" uniqKey="Unger M" first="M." last="Unger">M. Unger</name></author><author><name sortKey="Odin, P" sort="Odin, P" uniqKey="Odin P" first="P." last="Odin">P. Odin</name></author><author><name sortKey="Chaudhuri, K R" sort="Chaudhuri, K R" uniqKey="Chaudhuri K" first="K. R." last="Chaudhuri">K. R. Chaudhuri</name></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W. H." last="Oertel">W. H. Oertel</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:C6EDD2BA3F0B3B94A9BEE2F689AE5AB3CC998FB0</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1111/j.1468-1331.2008.02214.x</idno><idno type="url">https://api.istex.fr/document/C6EDD2BA3F0B3B94A9BEE2F689AE5AB3CC998FB0/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000757</idno><idno type="wicri:Area/Main/Curation">000660</idno><idno type="wicri:Area/Main/Exploration">000E45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clinical risk–benefit assessment of dopamine agonists</title><author><name sortKey="Moller, J C" sort="Moller, J C" uniqKey="Moller J" first="J. C." last="Möller">J. C. Möller</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps‐University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Eggert, K M" sort="Eggert, K M" uniqKey="Eggert K" first="K. M." last="Eggert">K. M. Eggert</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps‐University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Unger, M" sort="Unger, M" uniqKey="Unger M" first="M." last="Unger">M. Unger</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps‐University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author><author><name sortKey="Odin, P" sort="Odin, P" uniqKey="Odin P" first="P." last="Odin">P. Odin</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Klinikum‐Bremerhaven Reinkenheide, Bremenhaven</wicri:regionArea><wicri:noRegion>Bremenhaven</wicri:noRegion><wicri:noRegion>Bremenhaven</wicri:noRegion></affiliation></author><author><name sortKey="Chaudhuri, K R" sort="Chaudhuri, K R" uniqKey="Chaudhuri K" first="K. R." last="Chaudhuri">K. R. Chaudhuri</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>King’s College Hospital, University Hospital Lewisham, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W. H." last="Oertel">W. H. Oertel</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Neurology, Philipps‐University, Marburg</wicri:regionArea><placeName><region type="land" nuts="1">Hesse (Land)</region><region type="district" nuts="2">District de Giessen</region><settlement type="city">Marbourg</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">European Journal of Neurology</title><idno type="ISSN">1351-5101</idno><idno type="eISSN">1468-1331</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="2008-09">2008-09</date><biblScope unit="volume">15</biblScope><biblScope unit="supplement">s2</biblScope><biblScope unit="page" from="15">15</biblScope><biblScope unit="page" to="23">23</biblScope></imprint><idno type="ISSN">1351-5101</idno></series><idno type="istex">C6EDD2BA3F0B3B94A9BEE2F689AE5AB3CC998FB0</idno><idno type="DOI">10.1111/j.1468-1331.2008.02214.x</idno><idno type="ArticleID">ENE2214</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1351-5101</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>daytime sleepiness</term><term>depression</term><term>dopamine agonist</term><term>fibrotic reaction</term><term>gambling</term><term>punding</term><term>risk–benefit</term><term>tremor at rest</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists (DAs) have proven efficacy as monotherapy in early Parkinson’s disease (PD) for preventing motor complications such as dyskinesia and as adjunct therapy as the disease progresses. Further, it is increasingly evident that at least some DAs may provide additional benefits, such as reduction in depressive symptoms and treatment of refractory tremor. Different side‐effect profiles have been associated with levodopa and ergot or non‐ergot DA treatment, such as sudden onset of sleep, reduced impulse control, hallucination, and cardiovascular fibrosis. This paper discusses the evidence for specific associations between particular treatments and side effects as well as the clinical implications for patient care. Ultimately, the choice depends on the risk–benefit assessment as it applies to the individual patient’s clinical profile and the physician’s preference.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>District de Giessen</li><li>Grand Londres</li><li>Hesse (Land)</li></region><settlement><li>Londres</li><li>Marbourg</li></settlement></list><tree><country name="Allemagne"><region name="Hesse (Land)"><name sortKey="Moller, J C" sort="Moller, J C" uniqKey="Moller J" first="J. C." last="Möller">J. C. Möller</name></region><name sortKey="Eggert, K M" sort="Eggert, K M" uniqKey="Eggert K" first="K. M." last="Eggert">K. M. Eggert</name><name sortKey="Odin, P" sort="Odin, P" uniqKey="Odin P" first="P." last="Odin">P. Odin</name><name sortKey="Oertel, W H" sort="Oertel, W H" uniqKey="Oertel W" first="W. H." last="Oertel">W. H. Oertel</name><name sortKey="Unger, M" sort="Unger, M" uniqKey="Unger M" first="M." last="Unger">M. Unger</name></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Chaudhuri, K R" sort="Chaudhuri, K R" uniqKey="Chaudhuri K" first="K. R." last="Chaudhuri">K. R. Chaudhuri</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:C6EDD2BA3F0B3B94A9BEE2F689AE5AB3CC998FB0
|texte= Clinical risk–benefit assessment of dopamine agonists
}}
| This area was generated with Dilib version V0.6.23. |  |